OncoMatch/Clinical Trials/NCT06239727
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
Is NCT06239727 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for nasopharyngeal carcinoma.
Treatment: PD-1 blocking antibody · Gemcitabine · Cisplatin (80 mg/m2) · Cisplatin (100 mg/m2) · Capecitabine — This is an Open Label, Non-Inferiority, Multicenter, Randomized Phase 3 Trial aimed to investigate the impact of reduced-dose radiotherapy in combination with chemotherapy and immunotherapy on patients' prognosis and complication compared with conventional-dose radiotherapy in combination with chemotherapy and immunotherapy for treatment-sensitive stage III NPC patients screened out according to the treatment response.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage III
Excluded: Stage T3N0
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: induction chemotherapy (GP regimen, Camrelizumab) — induction
Receive 3 cycles of indction chemotherapy (GP regimen + Camrelizumab)
Cannot have received: radiotherapy
Exception: non-melanoma skin cancer located outside the target volume of radiotherapy for nasophayngeal carcinoma
History of radiotherapy, except for non-melanoma skin cancer located outside the target volume of radiotherapy for nasophayngeal carcinoma
Cannot have received: other local or regional therapy
Receive treatment for the local or regional disease other than that specified in the research plan
Lab requirements
Blood counts
white blood cell count > 4×10^9/l, hemoglobin > 90g/l, platelet count > 100×10^9/l
Kidney function
creatinine clearance rate ≥ 60 ml/min
Liver function
total bilirubin ≤ 1.5 × uln, alanine transaminase and aspartate transaminase ≤ 2.5 × uln, alkaline phosphatase ≤ 2.5 × uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify